Results 11 to 20 of about 38,540 (200)

Evaluation of Sensitivity and Resistance of Linezolid in Pre Extensively Drug Resistance Tuberculosis and Extensively Drug Resistance Tuberculosis at a Tertiary Care Hospital, Jamnagar, Gujarat, India [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2019
Introduction: The diseases have a high prevalence in India, accounting for one fourth of the Tuberculosis (TB) cases in the world. The situation becomes more complicated due to the rising of Human Immunodeficiency virus/AIDS pandemic, the emergence of ...
Dipali Maganbhai Gavali   +4 more
doaj   +1 more source

Linezolid use in German acute care hospitals: results from two consecutive national point prevalence surveys

open access: yesAntimicrobial Resistance and Infection Control, 2019
Background Linezolid belongs to a reserve group of antibiotics. In recent years, reports on linezolid resistance in gram-positive cocci have become more frequent. Overuse of linezolid is a relevant factor for resistance development. The objective of this
Tobias Siegfried Kramer   +5 more
doaj   +1 more source

Radezolid Is More Effective Than Linezolid Against Planktonic Cells and Inhibits Enterococcus faecalis Biofilm Formation

open access: yesFrontiers in Microbiology, 2020
The aim of this study was to compare the effects of radezolid and linezolid on planktonic and biofilm cells of Enterococcus faecalis. A total of 302 E.
Jinxin Zheng   +12 more
doaj   +1 more source

Low prevalence of Cfr-mediated linezolid resistance among methicillin-resistant Staphylococcus aureus in a Spanish hospital: case report on linezolid resistance acquired during linezolid therapy.

open access: yesPLoS ONE, 2013
Linezolid is an effective antimicrobial agent to treat methicillin-resistant Staphylococcus aureus (MRSA). Resistance to linezolid due to the cfr gene is described worldwide. The present study aimed to analyze the prevalence of the cfr-mediated linezolid
Josep M Sierra   +6 more
doaj   +1 more source

Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India

open access: yesJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020
Background: Multidrug-resistant tuberculosis (MDR-TB) is an increasing problem worldwide, and 24% occurs in India. Linezolid is associated with improved MDR-TB treatment outcomes but causes significant side-effects and drug susceptibility testing (DST ...
J.A. Tornheim   +3 more
doaj   +1 more source

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy

open access: yesmBio, 2015
Linezolid is an oxazolidinone with potent activity against Mycobacterium tuberculosis. Linezolid toxicity in patients correlates with the dose and duration of therapy. These toxicities are attributable to the inhibition of mitochondrial protein synthesis.
Ashley N. Brown   +10 more
doaj   +1 more source

Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more

open access: yesBMC Infectious Diseases, 2023
Background The elderly with severe infection increased dramatically in intensive care unit (ICU). Proper antimicrobial therapy help improve the prognosis.
Ying Xu, Xilan Yang, Pei Liang, Chen Qu
doaj   +1 more source

Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis

open access: yesFrontiers in Pharmacology, 2022
Multidrug-resistant tuberculosis (MDR-TB) remains a main global health concern as there is no comprehensive therapeutic intervention yet and numerous adverse effects follow the therapeutic process.
Yuan Yuan   +9 more
doaj   +1 more source

Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis.

open access: yesPLoS ONE, 2019
BackgroundLinezolid has shown strong antimicrobial activity against multidrug-resistant (MDR)/rifampin-resistant strains of Mycobacterium tuberculosis.
Yuan Li   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy